current reporting system for adverse drug reactions l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Current Reporting System for Adverse Drug Reactions PowerPoint Presentation
Download Presentation
Current Reporting System for Adverse Drug Reactions

Loading in 2 Seconds...

play fullscreen
1 / 28

Current Reporting System for Adverse Drug Reactions - PowerPoint PPT Presentation


  • 511 Views
  • Uploaded on

Current Reporting System for Adverse Drug Reactions. National Pharmaceutical Control Bureau Ministry of Health Malaysia www.bpfk.gov.my. WHO Collaborating Centre For Regulatory Control of Pharmaceuticals. Member of Pharmaceutical Inspection Cooperation Scheme. MS ISO 9001:2000 Certified.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Current Reporting System for Adverse Drug Reactions' - jacob


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
current reporting system for adverse drug reactions

Current Reporting System for Adverse Drug Reactions

National Pharmaceutical Control Bureau

Ministry of Health Malaysia

www.bpfk.gov.my

WHO Collaborating Centre

For Regulatory Control of Pharmaceuticals

Member of Pharmaceutical

Inspection Cooperation Scheme

MS ISO 9001:2000 Certified

slide2

Feedback given to registration holders

receive ADR report

report ADR

Pharmaceutical company

ADR form

National ADR centre

Health professionals

WHO

recommendations

Malaysian ADR Advisory Committee

(MADRAC)

Drug Control Authority

(DCA)

ADR MONITORING SYSTEM IN MALAYSIA

slide3

THE SPONTANEOUS REPORTING SYSTEM

Malaysia like most other countries uses a

spontaneous reporting system for ADR

Passive surveillance system

Health professionals are encouraged to

report adverse reactions which they believe

to be drug-related directly to

 the regulatory authority or

 the company marketing the suspected

product on a voluntary basis.

slide4

The spontaneous

reporting system

processes

1. data acquisition

which depends largely on the input

of information derived from reports

submitted by the health professionals

who have encountered what they

suspect is an ADR

The spontaneous reporting system

1.data acquisition

2.data assessment

3.data interpretation

slide5

The spontaneous reporting system

1.data acquisition

2.data assessment

3.data interpretation

The spontaneous

reporting system

processes:-

2. data assessment

which involves assessment of

the individual case reports and

assessment of pooled data

obtained from various sources

such as the international database

of the WHO

slide6

The spontaneous reporting system

1.data acquisition

2.data assessment

3.data interpretation

The spontaneous

reporting system

processes:-

3. data interpretation

based on the available data and

the assessments made, a signal

related to the adverse reaction

may be generated

malaysia adverse drug reactions advisory committee madrac
Malaysia Adverse Drug Reactions Advisory Committee (MADRAC)
  • As part of the regulatory process, a system to ensure the safety of the public consuming registered products was established through the monitoring of adverse drug reactions
  • MADRAC was established under the Drug Control Authority (DCA) to perform the function of monitoring safety profiles of drugs registered for use in Malaysia
slide8
MADRAC provides the DCA with information pertaining to drug safety issues which occur locally and internationally
  • The National Drug Safety Monitoring Centre, which is the secretariat to MADRAC, was accepted as the 30th member of the World Health Drug (WHO) Safety Monitoring Program in 1990.
  • Under the monitoring programme, all ADR reports which have been received and screened by MADRAC are submitted to the Uppsala Monitoring Centre in Sweden for inclusion into the WHO database
madrac mission
MADRAC Mission

To ensure the safety of Malaysians through the continuous assessment of the safety profiles of drugs registeredfor use in this country.

what madrac do
What MADRAC do?

Functions

  • Promote ADR reporting in Malaysia
  • Provide information and advice to the DCA in order that regulatory action can be taken based on the ADRs received (local & foreign).
  • Provide information to doctors, pharmacist and other health care professionals on ADRs.
  • Participate in the WHO ADR monitoring programme.
outcome of adr reporting
Outcome of ADR reporting
  • Suggest labeling changes to be made to the product insert/packaging e.g. warnings, boxed warnings, precautions, drug interactions, etc.
  • Recommend restrictions on usage e.g. not recommended for children, contraindicated in pregnancy, patients with certain risk factors.
  • Advocate control on sale of particular products
  • Implement drug recalls/withdrawal based on safety issues
from adr report to drug policy

Receive ADR report/information

FROM ADR REPORT TO DRUG POLICY

Verify information

Assessment

WHO

Discuss at MADRAC meeting

Requires regulatory action?

Prepare policy paper for DCA

IMPLEMENT POLICY

slide13

ADULTERATED PRODUCT

BAIKE WAN

  • BPFK received ADR/complaint from consumer stating that this product can relieve nerves and joint pain.
  • Product has been tested by BPFK and found to contain caffein and niacinamide and the registration of the product has been cancelled.
  • Although the registration of the product has been cancelled, BPFK still receives complaint that the product is available in the market.
slide14

ADULTERATED PRODUCT

BAIKE WAN

  • These reports were forwarded to the enforcement unit for further action since the product is an unregistered product.
  • BPFK also received complaint from other regulatory authorities stating that they have tested the product and found to be adulterated with scheduled poisons ie chlorpheniramine, frusemide and piroxicam.
  • Since the registration of the product has been cancelled and adulterated product is still available in the market and for the safety to the consumers, a press statement is made on this product
slide16

TO BE FAIR IS TO BE BEAUTIFUL

  • 1997:A young Malay lady called in to complain that she had used a whitening cream which initially was very effective
  • On continuous usage, her skin started to get hyperpigmented instead
  • Her face looked so terrible she did not even want to venture out of her house
slide17

Information on product used and where it was purchased was provided

  • Sample taken for testing and was found to contain 25% hydroquinone
  • Actions taken:
    • GMP audit done of manufacturing premise
    • Found gross violation of GMP principles
    • Manufacturer instructed to shut down
    • Total product recall
    • Decision made not to allow use of hydroquinone in Over-The-Counter products
who uppsala monitoring centre
WHO – Uppsala Monitoring Centre
  • WHO International Drug Monitoring Programme carried out by Uppsala Monitoring Centre (UMC) in Sweden.
  • UMC – responsible to collect ADR data from all over the world especially from countries that are members and the generation of signals of drugs which might possibly have problematic side-effects.
overview areas of work of the uppsala monitoring centre
Overview - areas of work of the Uppsala Monitoring Centre
  • Receipt, analysis and recording of worldwide adverse event data
  • Maintenance and screening of international database (currently over 3.9 million records)
  • Publication of previously unknown adverse events in SIGNAL
  • Editing, updating and publishing the WHO Drug Dictionary
  • Maintaining and publishing the Adverse Reaction Terminology (WHO-ART)
  • Carrying out special searches of the database by request
  • Publishing a range of special reports
slide20
Assistance to potential members of the Programme in developing their pharmacovigilance systems
  • Running training courses in pharmacovigilance
  • Organising the annual meeting for member and associate member countries
  • Publishing scientific articles
  • Contributing to international conferences.
  • WHO Drug Dictionary
  • WHO Adverse Drug Reaction Terminology
  • VigiFlow: A validated case management system for pharmacovigilance centres and companies
  • Data – mining and signaling
  • Monitoring Herbal Medicine and Herbal ATC Classification
who definition of signal
WHO definition of “SIGNAL”

“Reported information on a possible causal relationship between and adverse event and a drug, the relationship being unknown or incompletely documentedpreviously”

Additional note : Usually more than 1 report is required to generate a signal, depending on the seriousness of the event and the quality of information.

how signals can be detected
How Signals can be detected?
  • Manual investigation + clinical judgement

- Clinical review

- Search for and review

- Look at total number of reports

  • Quantitative Signal detection

- Proportional Reporting Ratio

- Reporting Odds Ratio

- Bayesian Confidence Propagation Neural Network (BCPNN) – a combination between Bayesian Statistic and a neural network implementation

international drug safety program
INTERNATIONAL DRUG SAFETY PROGRAM
  • Initiated in 1964 at the request of the World Health Assembly
  • Coordinated by the WHO
  • Started with 10 countries
  • To become a member, must have a national centre responsible for coordinating the program
  • Malaysia became the 34th member in 1990
  • Up to this date – 82 member countries

18 associate members

functions of the who programme for international drug monitoring include
Functions of the WHO Programme for International Drug Monitoring include
  • Identification and analysis of new adverse reaction signals from the case report
  • Provision of the WHO database as a reference source for signal strengthening and ad hoc investigations.
  • Information exchange between WHO and National Centres, mainly through 'Vigimed', an e-mail information exchange system
  • Publication of periodical newsletters, (WHO Pharmaceuticals Newsletter and Uppsala Reports), guidelines and books in the pharmacovigilance and risk management area
slide26
Supply of tools for management of clinical information including adverse drug reaction case reports
  • Provision of training and consultancy support to National Centres and countries
  • Computer software for case report management designed to suit the needs of National Centres (VigiFlow)
  • Annual meetings for representatives of National Centres at which scientific and organizational matters are discussed
  • Methodological research for the development of pharmacovigilance as a science.
measures taken to promote adr reporting
Measures taken to promote ADR reporting
  • Distribution of Manual on ADR reporting to all medical practitioners and pharmacists
  • ADR reporting forms with prepaid postage given free to doctors and pharmacists
  • Talks by MADRAC committee members to public and private sector doctors and pharmacists
  • Articles on ADR reports in local newsletter
slide28

THANK YOU

FOR YOUR

ATTENTION